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Background: Trefoil factors (TFF1, TFF2, and TFF3) are small secretory molecules that recently have gained signif-
icant attention inmultiple studies as an integral component of pancreatic cancer (PC) subtype-specific gene sig-
nature. Here, we comprehensively investigated the diagnostic potential of all the member of trefoil family,
i.e., TFF1, TFF2, and TFF3 in combination with CA19.9 for detection of PC.
Methods: Trefoil factors (TFFs) gene expression was analyzed in publicly available cancer genome datasets,
followed by assessment of their expression in genetically engineered spontaneous mouse model (GEM) of PC
(KrasG12D; Pdx1-Cre (KC)) and in human tissue microarray consisting of normal pancreas adjacent to tumor
(NAT), precursor lesions (PanIN), and various pathological grades of PC by immunohistochemistry (IHC).
Serum TFFs and CA19.9 levels were evaluated via ELISA in comprehensive sample set (n= 362) comprised of
independent training and validation sets each containing benign controls (BC), chronic pancreatitis (CP), and
various stages of PC. Univariate and multivariate logistic regression and receiver operating characteristic curves
(ROC) were used to examine their diagnostic potential both alone and in combination with CA19.9.
Findings: The publicly available datasets and expression analysis revealed significant increased expression of
TFF1, TFF2, and TFF3 in human PanINs and PC tissues. Assessment of KCmousemodel also suggested upregulated
expression of TFFs in PanIN lesions and early stage of PC. In serum analyses studies, TFF1 and TFF2 were signifi-
cantly elevated in early stages of PC in comparison to benign and CP control group while significant elevation in
TFF3 levels were observed in CP group with no further elevation in its level in early stage PC group. In receiver
operating curve (ROC) analyses, combination of TFFswith CA19.9 emerged as promising panel for discriminating
early stage of PC (EPC) from BC (AUCTFF1+TFF2+TFF3+CA19.9 = 0.93) as well as CP (AUCTFF1+TFF2+TFF3+CA19.9 =
0.93). Notably, at 90% specificity (desired for blood-based biomarker panel), TFFs combination improved
CA19.9 sensitivity by 10% and 25% to differentiate EPC from BC and CP respectively. In an independent blinded
validation set, the combination of TFFs and CA19.9 (AUCTFF1+TFF2+TFF3+CA19.9= 0.82) also improved the overall
efficacy of CA19.9 (AUCCA19.9=0.66) to differentiate EPC from CP proving unique biomarker capabilities of TFFs
to distinguish early stage of this deadly lethal disease.
Interpretation: In silico, tissue and serum analyses validated significantly increased level of all TFFs in precursor
lesions and early stages of PC. The combination of TFFs enhanced sensitivity and specificity of CA19.9 to discrim-
inate early stage of PC from benign control and chronic pancreatitis groups.
© 2019 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Pancreatic cancer (PC) is an aggressive diseasewith a five-year over-
all survival rate of b8%. It is the third‑leading cause of cancer-related
deaths worldwide, and by 2030, it is projected to escalate to second
rank of cancer-related death [1,2]. While the five-year survival rate of
patients with localized PC is 34.3%, unfortunately, only 10% of total PC
patients are diagnosed at an early stage. Approximately 52% of cases
are diagnosed at late/metastasized stage, with a worsened five-
survival rate of only 2.7% [2]. Considering these dire statistics, early de-
tection is key to improved PC patient survival. Therefore, identification
of early diagnostic biomarkers may result in a timely therapeutic inter-
vention and lead to improve patient prognosis.
To characterize a prospective diagnostic signature for PC, a compen-
dium of several secretory andmembranous proteinswas enlisted as po-
tential biomarker candidates that demand methodical validation for
clinical effectivity [3]. Among the identified 160 secretory molecules,
trefoil factors (TFF1, 2 and 3 (TFFs)) were recognized as potential
markers for PC [3]. TFFs are small, secretory mucin-associated proteins
known to protect epithelial cells from various environmental insults
[4]. Although under physiological conditions they protect the gastric
mucosa from inflammation, the oncogenic role of TFFs has been ob-
served in multiple malignancies, including breast, prostate, ovarian,
and colon cancers [5]. The secretory nature of TFFs, and their high resis-
tance to proteolytic digestion, acid, and heat degradation qualify them
as advantageous from a biomarker perspective.
We aimed to explore the individual and combined diagnostic poten-
tial of TFFs alone and in combination with CA19.9 in PC. Although they
were previously recognized as promising biomarkers, there has been
no comprehensive study assessing the diagnostic capability of TFFs for
early detection of PC. To evaluate this potential, we explored publicly
available datasets of PC, followed by validation of expression via immu-
nohistochemistry (IHC) in the genetically engineered spontaneous
mouse model of PC progression and human tissues comprising of nor-
mal pancreas adjacent to tumor (NAT), PC precursor lesions (PanIN),
and PC tissues. We further evaluated circulatory TFF levels in the sera
obtained from training and validation clinical cohorts of PC patients
and control samples and analyzed the biomarker potential of individual
TFFs in combinationwith CA19.9. This study reports a potential diagnos-
tic biomarker panel to identify early-stage PC with improved sensitivity
(SN) and specificity (SP).
2. Materials and methods
2.1. Ethics statement
Training and validation sets were obtained from University of Pitts-
burghMedical Center (UPMC, IRB number PRO07030072), withwritten
consent from all patients before enrollment in the study. Tissue micro-
arrays were obtained from Rapid Autopsy Program (RAP), University
of Nebraska Medical Center (IRB-#091-01) with written consent from
the patients before tissue collection.
2.2. Trefoil factor expression in publicly available PC datasets
GEO datasets containing PC-specific gene expression and patient
clinical information were used to assess expression of TFFs. Further, to
make the comparisons statistically significant and reduce any chance
of method-induced statistical bias, two independent datasets
(GSE16515 and GSE43288) were selected containing normal pancreas,
PanIN, and PC samples. For dataset GSE43288, samples were profiled
using Affymetrix Human Genome U133A Array (Affymetrix, Inc., Santa
Clara, CA), which contains normal pancreas (n = 3), PanIN (n = 13)
and PC (n =4) tumor tissues, while dataset GSE16515 samples were
profiled using Affymetrix Human Genome U133 Plus 2.0 Array
(Affymetrix, Inc., Santa Clara, CA) and contain normal pancreas (n =
16) and PC (n = 36) tumor tissues [6]. Briefly, the raw CEL files were
first downloaded and background-corrected. Expression was calculated
using the quantile normalization method robust multi-array average
(RMA) within the same package for each dataset. The normalized
gene expression values (RMA) for TFFs in normal, PanIN, and PC were
plotted using MedCalc software. We also analyze all TFFs expression
from cBioPortal database, a freely available dataset which is comprised
of published and provisional TCGA datasets consisting of 169 studies
from 30 different tumor types.
2.3. Tissue immunohistochemistry (IHC) and immunofluorescence for TFF1,
TFF2 and TFF3
Immunohistochemistry analyses were performed on commercial
tissue microarray (TMA) (Biomax, USA) as well as TMA from the rapid
autopsy program (RAP) at UNMC). Tissue spots on the Biomax TMA
(BIC14011, OD-CT-DgPan03-001, OD-CT-DgPan01-006) were exam-
ined by their own pathologists to determine the pathological grading
Research in context
Evidence before this study
Pancreatic cancer (PC) subtype studies highlight the upregulation
of all the members of Trefoil Factors (TFF1, TFF2, and TFF3) in
classical subtypes of pancreatic cancer. Further, global
transcriptomic studies indicate differential expression of TFFs in
precursor lesion and pancreatic cancer cases. However, to date,
there is no comprehensive study exploring the diagnostic potential
of all Trefoil Factors in pancreatic cancer.We searched in PubMed
and Google Scholar for papers published before Aug 10, 2018,
with the terms “biomarker Trefoil Factors in pancreatic cancer”
OR “diagnostic significance of trefoil factor in pancreatic cancer”
OR “TFF1, TFF2 and TFF3 in pancreatic cancer” with no language
restrictions. TFF1 emerged as an urinary biomarker for early detec-
tion of PC in combinatorial panel with LYVE-1, REG1A. To our
knowledge, there is no published study that explores the diagnos-
tic potential all Trefoil Factors alone or in combination with
CA19.9 to diagnose PC utilizing serum/plasma samples.
Added value of this study
Comprehensive analyses of gene datasets, human pancreatic pre-
cursor lesions, and tumor tissues revealed differential expression
of all the members of TFF family, i.e. TFF1, TFF2, and TFF3, in
precursor lesions and during the progression of PC. Differential ex-
pression of TFFs is observed in pancreatic precursor lesions from
genetically engineered mouse models of PC progression. In addi-
tion to pancreatic precursor lesions and tumor tissues, elevated
levels of TFFs were observed in serum samples from early and
late stage PC cases. Combination of TFFs and CA19.9 has im-
proved overall diagnostic accuracy with increased sensitivity and
specificity for detecting early stage of PC in comparison to
CA19.9 alone both in training and independent validation sets.
Implications of all the available evidence
The multimarker panel combining of TFF1, TFF2, TFF3, and
CA19.9 holds the potential to predict the lethal PC at an early
stage. Overall, these findings are clinically relevant, as early diag-
nosticmarker for PC is urgently needed not only for disease detec-
tion but also to lead for more targeted approaches for treating
patients with this disease.
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and staging. This array contained spots from healthy normal or normal
adjacent to the pancreatic tumor, chronic pancreatitis (CP), and PC of
different stages and grades. For immunohistochemical staining of
mouse TFF1, TFF2 and TFF3 in the paraffin-embedded mouse tissues,
10, 20, and 30 week old floxed KrasG12D Pdx1-Cre mouse tissues (posi-
tive for both Kras and Pdx1-Cre), and their age-matched littermate con-
trols (n = 3 animals per age group), were processed using methods
describing previously [7]. Briefly, after deparaffinization with xylene
and subsequent rehydration with ethanol, epitope retrieval was
achieved by boiling the slides in citrate buffer (pH 6.0) for 15min. En-
dogenous peroxidase activity was quenched by immersing the TMAs
in hydrogen peroxidase solution [0.3% hydrogen peroxidase in 1:1 solu-
tion of methanol: water] for 1 h. at room temperature, in the dark. Tis-
sues were next blocked with horse serum (ImmPRESS Universal
antibody kit; Vector Laboratories, Burlingame, CA) for 2h. at room tem-
perature. Subsequently, the TMAs were incubated with individual pri-
mary antibodies for TFF1 (1:200, ab92377, Abcam, Cambridge, MA),
TFF2 (Protein tech, 1:500) and TFF3 (ITF Antibody (FL-80): sc-28927,
Santa Cruz for human tissue, for mouse tissue TFF3 antibody was kindly
provided by Daniel K. Podolsky, UT Southwestern Medical Center, Dal-
las, TX). After overnight incubation with primary antibodies, the slides
were washed four times with PBS, followed by incubation with horse-
radish peroxidase (HRP)–conjugated secondary antibody (ImmPRESS
Universal antibody kit; Vector Laboratories, Burlingame, CA) for 1 h. Fol-
lowing secondary antibody incubation, the TMAs were washed with
PBS and color was developed using DAB solution (3,3′-diaminobenzi-
dine solution) (DAB substrate kit; Vector Laboratories, Burlingame,
CA). Once the reddishbrown precipitate was developed, the peroxidase
reaction was quenched using distilled water, and sections were coun-
terstained with hematoxylin for 1–2min. After that, dehydration in an
increasing percentage of ethanol followed by three consecutive wash-
ings with xylene were performed. Finally, the sections were mounted
using Vecta-mount mounting medium (Vector Laboratories). Each tis-
sue spot was evaluated by pathologist for the H-score, which is the
product of the percentage of cells positive in the area for each TFF and
intensity of staining on a 0–3 scale (0= no staining, 1=weak staining,
2 = moderate staining and 3 = strong staining). Colorectal cancer tis-
sueswere used as positive controls and isotype controlwas used as neg-
ative control (image not shown). The slides were scannedwith Ventana
iScan HT from (Ventana Medical Systems, Inc.; Roche Group, Tucson,
AZ).
For tissue immunofluorescence studies on TFFs, the initial steps up
to blocking were similar to those of IHC. Following blocking, the slides
were incubated with an appropriate dilution of primary antibodies
(1:25, 1:50 and 1:25 for TFF1, TFF2, and TFF3 respectively, the same an-
tibody used for immunohistochemistry) overnight at 4 °C. Primary anti-
body detection and visualization of TFF1–3was achieved by Alexa Fluor
488 labeled goat anti-rabbit IgG2b (Invitrogen Molecular Probes, Eu-
gene, OR, diluted 1:200), incubated for one hour and then washed
with PBS three times. Finally, the sections were mounted using an
anti-fading mounting medium containing DAPI (Vectashield H-1500;
Vector Laboratories). The stained sections were analyzed by confocal
scanning laser microscopy, using an LSM 510 Meta laser scanning mi-
croscope (Carl Zeiss, Jena, Germany).
2.4. Sandwich Enzyme-Linked Immunosorbent Assay (ELISA)
Individual TFF levels in serum were measured quantitatively by
sandwich ELISA in accordance with manufacturer instructions, using
the DuoSet ELISA kit with few modifications (R&D Systems, Catalog
for TFF1: DY5237, for TFF2: DY4077, and for TFF3: DY4407). Before
performing the analysis, assay optimizationwas performed to select ap-
propriate positive controls and the sample dilution factor to be used for
ELISA. Standard curves were produced from standard providedwith the
kit. TFF1 and TFF2 standardswere serially (log2) diluted from250 pg/ml
to 0.4 pg/ml, and TFF3 standard from 750 pg/ml to 1.46 pg/ml. A
detailed ELISA protocol is provided in the supplementary section. For
the detection step, instead of using the manufacturer provided
streptavidin-HRP, we used Pierce Streptavidin Poly-HRP (Thermo Sci-
entific, USA), (diluted to 0.4 μl/ml in 1% BSA) and incubated for 20 min
in the dark at room temperature. ELISA plates were read at 450 nm
with an absorbance correction at 540 nm. Appropriately diluted sample
lysates from TFF expressing cell lines were used as a positive control
(MCF7 breast cancer cells for TFF1, LS174T colon cancer cell line for
TFF2 and AsPC-1 PC cell line for TFF3). According to manufacturer's
datasheet, there is no cross-reactivity across TFFs in ELISA assays.
CA19.9 serum levels were measured using DRG® CA 19–9 ELISA (EIA-
3940) kit (DRG International, Inc., NJ, USA). Serum sampleswere diluted
(50 fold) appropriately to obtain absorbance in the linear range of the
assay. The Area Under Curve (AUC) for CA19.9 analysis was performed
with the standard clinical cutoff value (37 U/ml) [8]. All samples were
tested in duplicate. Data were analyzed using SOFTMAX PRO software
(Molecular Devices Corp., Sunnyvale, CA).
2.5. Study cohorts
Two independent sets of samples (training and validation sets) were
used to assess the diagnostic performance of TFFs in PC patient serum.
The training set (n = 304) included benign control (BC, n = 104),
chronic pancreatitis (CP, n = 47), and PC (n = 153). Within the PC
group, samples from early stage (EPC, Stage 1 and 2, n= 80) and late
stage PC (LPC, Stage 3 and 4, n= 73) were segregated for further anal-
ysis. Serum samples were shipped from UPMC by overnight mail to the
University of Nebraska Medical Center (UNMC) for all experimental
analyses. PC staging was determined surgically, based on operative pa-
thology, biopsy of metastatic disease, or radiographic imaging studies.
The grade, location of the tumor and stagewere based on reviewed hos-
pital records. Patients with benign pathologies such as duodenal ulcers,
choledochocele, common bile duct stones, benign stricture, biliary dila-
tion, or abnormal imaging on computed tomography or magnetic reso-
nance imaging scans of the pancreas were categorized as BC. The
independent blinded validation set was comprised of BC, CP, and PC
for which serum samples were collected and stored at UPMC. In both
training and validation cohort, all samples from UPMC were collected
pretreatment (pre-surgery, pre-chemotherapy). Diagnostic significance
of TFFs were further assessed in an independent blinded validation set
(n = 58) containing BC (n= 8), CP (n = 27) and PC (n = 23). In our
validation cohort, the PC samplesmajorly consisted of EPC (n=18). Pa-
tient demographic information for both training and validation datasets
is included in the Supplementary Table ST1a-b.
2.6. Statistical analysis
Serum concentration of each proteinwas calculated using GraphPad
software (GraphPad Software, Inc., San Diego, CA). Logarithm transfor-
mation was applied to all serum analyses. If the biomarker had a zero
level, before log transformation, the zero was changed to half the next
lowest value for that marker. Biomarker levels were compared among
assay groups with ANOVA. If the overall test was significant, then
pairwise comparisons were conducted, adjusting for multiple compari-
sons with Tukey'smethod. Patient characteristicswere compared by di-
agnosis using chi-square or Fisher's exact test for categorical variables
and ANOVA for continuous variables. TFF1, TFF2, and TFF3 levels were
compared with patient clinicopathological characteristics using t-tests
or ANOVA. We examined the correlation between markers using Pear-
son correlation. Univariate and multivariate logistic regression and
ROC curves were used to test individual markers and combinations as
predictors of disease status. ROC curves were used to determine the op-
timal marker cut points for discriminating the potential of an individual
protein. SAS software version 9.3 was used for data analysis (SAS Insti-
tute Inc., Cary, NC).
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3. Results
3.1. Expression of TFFs in PanIN lesions and PC from publicly available can-
cer genome dataset
We began our explorationwith the analysis of TFF1, 2, and 3 expres-
sions in PC using publicly available data sets (GSE43288, GSE16515).
Analyzing both data sets, we observed differential expression of all
TFFs in PanINs and PC compared to normal controls (Fig. 1 a&b). Signif-
icant upregulation of TFFswas observed in PanIN (TFF1, P b .005; TFF2, P
b .005 and TFF3 P b .05, Mann-Whitney U Test) as compared to normal
control (Fig. 1a). Similar upregulation of TFFs was observed in PC sam-
ples compared to normal control (Fig. 1b). In line with these results,
our analysis of the TCGA genome database from cBioPortal (http://
www.cbioportal.org) also showed that TFFs are widely expressed in a
variety of cancers, predominantly pancreas, colorectal, breast, and pros-
tate (Supplementary Fig. S1a-c) [9,10]. Interestingly, TFF1 was found to
bemost differentially expressed in PC followed by breast and other ma-
lignancies (Supplementary Fig. S1a). Similarly, the highest expression of
TFF2 was observed in PC followed by colorectal cancer (Supplementary
Fig. S1b). Slightly deviating from TFF1 & TFF2, the highest expression of
TFF3 was observed in colorectal cancer, followed by PC (Supplementary
Fig. S1c). All members of the TFF family were highly expressed in pan-
creatic tumors, in comparison to other malignancies. Based on the dif-
ferential upregulation of TFFs from the genomic data, we next sought
to comprehensively analyze the expression of TFFs in a panel of PanIN
and PC tissues as well as in serum samples.
3.2. Expression of TFFs in human clinical samples and spontaneous mouse
model of PC
After observing upregulation of TFFs in PC using available data sets,
we analyzed their expression in TMAs representing human NAT,
PanIN, and PC tissues (Fig. 2a). In corroboration with our genomic
data, we observed significant upregulation of all TFFs in PanIN lesions
and different grades of PC. No expression of any TFF was detected in
NAT. Strong expression of TFFs was observed in PanINs, well differenti-
ated (WD), andmoderately differentiated (MD) PC tissues,withmoder-
ate expression inpoorly differentiated (PD) tissues (Fig. 2a). TheH-score
of TFFs was found to be significantly higher for PanIN I-III (P b .0005 for
TFF1, P b .005 for TFF2 and P b .05 for TFF3), WD (P b .0005 for TFF1, P b
.005 for TFF2 and TFF3) andMD (Pb .0005 for TFF1, P b .005 for TFF2 and
TFF3), as compared to normal pancreatic tissue adjacent to tumor (NAT)
(Welch's t-Test) (Fig. 2a). Similar results of differential TFFs expression
in well-differentiated tumor were also observed using immunofluores-
cence (Supplementary Fig. S2a).We also observed strong positive stain-
ing of all TFFs inmetastatic liver tissues (5/5) (Supplementary Fig. S2b).
Strong expression of TFF3was observed in the Islet of Langerhans (Sup-
plementary Fig. S2c) while no expression of other two TFFs were ob-
served. Overall, our results demonstrated elevated expression of all the
TFFs in PanINs, well-differentiated and moderately differentiated tu-
mors in comparison to normal ducts. Given the significant overexpres-
sion in early stages of PC development, we reasoned that TFFs can
have the potential for early diagnosis of PC, even before the onset of
symptoms. Considering the lack of early-stage tumor tissue,we next an-
alyzed the expression of TFF1, 2, and 3 in awell-characterized spontane-
ous PC mouse model (KrasG12D; Pdx1-Cre) (KC) that recapitulates
genetic and histopathological features of early stages of PC [11]. Using
IHC analysis, we observed differential expression of all mouse TFF1, 2,
and 3 in KC animal at various weeks representing precursor lesion and
early stage of PC respectively (Fig. 2b).
3.3. Circulating levels of TFFs in clinical samples
To investigate the diagnostic potential of TFFs in PC, we analyzed
their levels in PC patient serum samples, using ELISA. The demographic
and clinical characteristics of patients were detailed in methods and
materials section. The training set is comprised of BC, CP, EPC, and LPC
patient serum samples. We observed that the median serum levels
of TFF1 in patients with BC, CP, EPC, and LPC were 257 pg/ml
(Inter Quartile Range, IQR: 156–616 pg/ml), 270.26 pg/ml (IQR:
185–574 pg/ml), 370.41 pg/ml (IQR: 214–1002 pg/ml), and 303 pg/ml
(IQR: 186–589 pg/ml) respectively. The median serum levels of TFF2
in patients with BC, CP, EPC, and LPC were 3768 pg/ml (IQR:
2510–5322 pg/ml), 3683 pg/ml (IQR: 2679–7450 pg/ml), 5792 pg/ml
(IQR: 3518–8932 pg/ml), and 4807 pg/ml (IQR: 2757–7556 pg/ml), re-
spectively. Themedian serum levels of TFF3 in patientswith BC, CP, EPC,
and LPC were 9348 pg/ml (IQR: 6728–13,223 pg/ml), 11,945 pg/ml
(IQR: 7452–19,149 pg/ml), 11,168 pg/ml (IQR: 7756–19,865 pg/ml),
and 9183 pg/ml (IQR: 6329–14,851 pg/ml), respectively. TFFs levels
are plotted on a logarithm scale (Fig. 3 a-c). The median serum level
of TFF1 was significantly higher in EPC as compared to BC (P b .005)
and CP (P b .05, ANOVA) (Fig. 3a). Serum levels of TFF2 were also signif-
icantly higher in the EPC group compared to BC and CP (Fig. 3b). In con-
trast, a significant elevation in TFF3 was observed in the CP group
compared to the BC group (P b .01, ANOVA), with no further change ob-
served during PC development (Fig. 3c). Of interest, differential circulat-
ing levels of TFFs were observed in late stages of PC as well in
comparison to BC and CP, however, their levels were comparatively
lower than the early stage cases (Fig. 3a-c).
We also investigated the possible correlations between TFFs and
clinicopathological variables such as gender, age, race, bilirubin level,
and alcohol history. No apparent difference was observed in the mean
value of TFF levels across gender, alcohol history, race (African
American, Asian & Caucasian) and bilirubin level. We noted that levels
of TFFs have a strong correlation with age (P b .0001, P= .0004 and P
=.0014 for TFF1, TFF2, and TFF3, respectively, ANOVA) (Supplementary
Table ST2). Circulatory levels of all TFFs were significantly high in pa-
tients aged N64 (Supplementary Table ST2).
3.4. Diagnostic performance of TFF1-3 individually and in combination in a
training cohort
Considering upregulated expression of TFFs across disease groups,
we next sought to explore their diagnostic potential either alone or in
combination to differentiate various stages of PC from benign controls.
The diagnostic performance of TFFs alone was assessed by using ROC
curve analysis (Table 1). In discriminating BCs from PC, individual TFFs
showed moderate discriminatory potential with SN/SP values for TFF1,
TFF2, and TFF3 being 0.72/0.46, 0.52/0.77 and 0.53/0.64, respectively,
and AUCs 0.61, 0.64, and 0.58, respectively (Table 1, Fig. S3a). For differ-
entiating CP from PC, SN/SP values for TFF1, TFF2, and TFF3 were 0.84/
0.36, 0.68/0.53, and 0.46/0.65, respectively, and AUCs of 0.62, 0.58, and
0.55, respectively (Table 1, Supplementary Fig. S3a). We also analyzed
whether the ratio of circulating individual TFF levels that could differen-
tiate between disease groups. Among all possible ratios, TFF1/TFF3
showed the most promising potential to differentiate between PC vs.
CP (AUC = 0.71) and EPC vs. CP, (AUC = 0.73) (Supplementary
Fig. S3b).
We next analyzed the diagnostic performance of TFFs in combina-
tion of two in each group (Supplementary Table ST3a). For this, we
first assessed correlation across TFFs and disease group. Our results sug-
gested that the Pearson correlation coefficient was significantly higher
between TFF1 and TFF3 (r=0.514, P= .0003) in the CP group (Supple-
mentary Fig. S4). Interestingly, this dual combination of TFF1 and TFF3
could distinguish PC and EPC from CP, AUCs of 0.71 and 0.72, respec-
tively (Supplementary Table ST3a). As discussed earlier, TFFs has
shown age-dependent variation, we performed the overall analysis
with age-adjustment taking into account those samples who are
N40 years and surprisingly, we have seen combination of TFF1 and
TFF3 made an overall improvement of differentiating PC and EPC from
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Fig. 2.Differential expression of TFF1–3 in tissues from precursor lesions, PC tissues from spontaneous PCmouse models and human PC. (a) Immunohistochemical analysis for individual
TFF were performed on pancreatic tissue microarrays (TMAs) containing normal pancreatic tissue adjacent to tumor (NAT) (TFF1, n= 39;TFF2, n= 8; TFF3, n= 41), pancreatic cancer
precursor lesions (PanIN I, II and III), (TFF1,n=32;TFF2, n=16; TFF3, n=10)well-differentiated (WD) (TFF1, n=13;TFF2, n=13; TFF3,n=11),moderately-differentiated (MD) (TFF1,
n=40;TFF2, n=40; TFF3, n=121) and poorly-differentiated (PD) (TFF1, n=9;TFF2, n=9;TFF3, n=10) pancreatic tumor tissues. No expression of TFF1, TFF2, and TFF3were observed
in normal pancreatic ducts while elevated expression was observed in the ductal compartment across a spectrum of precursor lesions as well as various stages of pancreatic tumor
differentiation. Scale bar for upper represents 500 μm and lower panel magnification represents 100 μm. Corresponding box and whisker plot representing quantitative H-score for
TFFs expression across NAT, PanINs and pancreatic tumor tissues. Significant overexpression of TFFs was observed in pancreatic tumor tissues in comparison to normal pancreas. ***P b
.0005, **P b .005, *P b .05, determined by Welch t-Test. (b) Immunohistochemical analysis of all mouse TFF (mTFF1, mTFF2, & mTFF3) protein expression levels throughout the
progression of PC in the spontaneous KrasG12D Pdx1-Cre (KC) mouse model, from 10 weeks to 30 weeks. Expression of TFF1, TFF2, and TFF3 was progressively increased from 10 to
30 weeks. Scale bars are 100 μm (n= 3 animals/age groups).The interquartile range (IQR) for TFFs expression is presented by corresponding box and whisker plot (Middle horizontal
line represents the median value). *P b .05 is determined by student t-test.
Fig. 1.Differential expression of TFF1, TFF2, and TFF3 in PC genomic datasets. (a) Representative box andwhisker plots depict the comparison of normalized expression of TFF1–3mRNA in
GSE43288dataset across normal pancreas (n=3), PC precursor lesions i.e. PanIN (n=13) and pancreatic tumor (PC) tissues (n=4). (b) Representativebox andwhisker plots comparing
normalized expression of TFF1–3mRNA inGSE16515 dataset across normal pancreas (n=16), andpancreatic tumor tissues (n=36). The interquartile range (IQR) for TFF1–3 expression
is presented by box and whisker plot (horizontal line represents the 25th percentile, median and 75th percentile and whisker represents 5th and 95th percentile). Publicly available
datasets were obtained from Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/). Significantly elevated expression of all the TFFs were observed in pancreatic tumors.
Further, the elevation in TFFs was found to be significantly higher across precursor lesions of PC. P values were determined using the Mann-Whitney U test (two-tailed). Red triangle
represents outlier value.
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CP with AUCs of 0.81 and 0.82, respectively (Supplementary
Table ST3b).
A combination of all TFFs demonstrated an AUC of 0.66 (95%CI,
0.59–0.74) with SN/SP 0.73/0.54 to segregate PC from BC. A similar pre-
diction trend was observed for this panel to distinguish EPC from BC.
Compared to any single TFF, the combination panel of TFFs showed sig-
nificant improvement in differentiating PC from CP, with an AUC 0.76
and SN/SP of 0.47/0.92 (Table 2). Similarly, to distinguish early-stage
PC from CP, the panel achieved an AUC value of 0.76 with SN/SP 0.51/
0.90. Values of AUC and sensitivity/specificity at optimal cutoffs are pre-
sented in Table 2. Our analysis suggested that, with age adjustment
combination of all TFFs has shown better performance in differentiating
PC or EPC from CP (AUC of 0.76 without age adjustment and 0.85 with
age adjustment) (Table 2 and Table ST4b). Values of AUC and SN/SP at
optimal cutoffs for dual combinations of TFFs without and with age-
adjustment are presented in Supplementary Table ST3a and 3b
respectively.
3.5. The combination of TFFs with CA19.9 improves diagnostic performance
The Pearson correlation coefficient (r)was used to delineate the cor-
relation between TFF and CA19.9 serum levels (Supplementary Fig. S4).
A positive correlation was observed for TFF1 and CA19.9 in BC (r =
0.217, P= .033) and a non significant positive correlation observed in
EPC (r = 0.226, P = .6). Significant positive correlation was also ob-
served for TFF2 and CA19.9 (r=0.389, P= .013) in the CP group (Sup-
plementary Fig. S4). Of note, a significant negative correlation was
observed between TFF2 and CA19.9 in EPC (r = −0.186, P = .017),
whereas a significant positive correlation was observed in LPC (r =
0.276, P= .055). Additionally, a positive but not significant correlation
was observed for TFF3 and CA19.9 in all the groups (Supplementary
Fig. S4). Our correlation analysis suggested that these markers can be
complementary to each other in various groups, which can improve
the overall efficacy of diagnosis.
As individual TFF showed moderate discriminatory potential and
positive correlation with CA19.9, we next investigated the diagnostic
performance of all TFF in combination with CA19.9. Our purpose was
to analyze whether various combinations of TFFs can improve the diag-
nostic ability of CA19.9. CA19.9 differentiated PC from BC with SN/SP
0.86/0.81 (Fig. 4a, Table 2). Combining TFFs with CA19.9 showed im-
proved efficiency to distinguish PC from BC with AUC 0.94 (95%CI,
0.87–0.99) compared to CA19.9 alone, AUC 0.91 (95%CI, 0.87–0. 95)
(Fig. 4a, Table 2). Sensitivity also increased from 0.76 to 0.85 (at 90%
specificity), to discriminate between PC and BC (Table 2). To discrimi-
nate between EPC and BC, the panel showed an interesting 10% increase
in sensitivity (at 90% specificity) compared to CA19.9 alone (Table 2). In
the case of discerning PC from CP, the AUC value escalated from 0.91,
(95%CI 0.86–0.95) to 0.94, (95%CI, 0.90–0.98) (Table 2). The combina-
tion of all four markers dramatically improved SN/SP of CA19.9 from
0.87/0.81 to 0.92/0.92 to differentiate EPC from CP (Table 2). Moreover,
a 16% rise in sensitivity (at 90% specificity) was observed to distinguish
PC from CP. Analysis of EPC and CP also demonstrated a sharp increase
of sensitivity from 0.67 to 0.92 (at 90% specificity) after the addition of
all TFFs to CA19.9 (Table 2). In the case of differentiating LPC from BC
or CP, the panel reasonably improved sensitivity and specificity as
well as the overall AUC value (Table 2). AUC values and SN/SP of this
panel for the different groups (at optimal cutoffs as well as sensitivity
at 90% specificity) for the panel are presented in Table 2. Optimal
cutpoints and models to determine SN/SP for CA19.9 and combination
of TFFs and CA19.9 are presented in Supplementary Table ST4a. Again,
when we analyzed our sample with age-adjustment, we observed sim-
ilar results to differentiate EPC from CP as compared to without age ad-
justment (Supplementary Table ST4b). The overall performance of all
possible combination of TFF with CA19.9 without age adjustment are
depicted in Supplementary Fig. S5 and Supplementary Table ST4c.
One of the drawbacks of standard CA 19.9 is that 5–10% people do
not express CA19.9 and therefore possess a risk of false negative results
[12]. Our finding demonstrates differential correlation between CA19.9
and TFF1–3, which suggests that their addition should complement
CA19.9 to identify PC. In light of this, we next sought to identify the di-
agnostic role of TFFs in low expressing CA19.9 (b37 U/ml) and high ex-
pressing CA19.9 (N37 U/ml) PC patient samples, assuming a likely
possibility that low CA19.9 PC patients are Lewis negative. We grouped
the patients based on the well-established and recommended cut-off
value for CA19.9, 37 U/ml [13]. We found that a combination of
TFF1–3 can better discriminate EPC from BC in low CA19.9 expressing
group, AUC- 0.74, than in high CA19.9 expressing group, AUC 0.69.
(Fig. 4b). The ability to discriminate between EPC and CP was also im-
proved in low vs. high expressing CA19.9 groups, AUC 0.87 vs. 0.71,
and SN/SP 1/0.62 vs. 0.92/0.46 (Fig. 4b, Supplementary Table ST5a and
b). As demonstrated with these correlation and ROC curve results, a
combination of TFF1–3 can complement CA19.9 to determine PC status.
Additionally, as we have observed age-dependent elevation of TFFs,
we performed age-matched analysis of diagnostic potential of TFFs in
Fig. 3.Higher levels of TFF1–3 are present in circulation during the early stages of PC. To evaluate diagnostic significance of TFFs, their levelswere quantified in serum from various control
group (benign controls (BC, TFF1, n=104;TFF2, n=92; TFF3, n=98),and chronic pancreatitis (CP, TFF1, n=47;TFF2, n=40; TFF3, n=46) alongwith early (EPC (Stage 1 and 2, TFF1, n
= 78;TFF2, n = 58; TFF3, n = 77) and late stage PC cases (LPC, stage 3 and 4, TFF1, n = 69;TFF2, n= 52; TFF3, n = 64) using duoset sandwich ELISA assay following manufacturer
instructions (R&D). (a-c) Box and whisker plots showing log [10] transformed serum levels (pg/ml) of TFF1, TFF2 and TFF3 for benign control (BC), chronic pancreatitis (CP), early-
stage PC (EPC, stage I and II) and late stage PC (LPC). The plot shows a significant increase in serum level of TFF1, TFF2, and TFF3 in EPC group as compared to BC. Box and whisker
limits represent the fifth and 95th percentiles; the box limits represent IQR where the horizontal lines represent 25th, median and 75th percentile the median concentration of each
group. P values are shown above the plots. The P-values were determined by the ANOVA. BC, benign control group; CP, chronic pancreatitis; EPC, early-stage pancreatic cancer (stage 1
and 2); LPC, late-stage pancreatic cancer (stage 3 and 4).
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low and high CA19.9 group. Surprisingly, after age adjustment in both
high and low CA19.9 groups, combination of TFFs has demonstrated
an AUC of 0.92 with SN/SP of 0.80/0.91 to differentiate PC (n = 10)
from CP (n = 23) in low CA19.9 (b37 U/ml) group, whereas, in high
CA19.9 group it showed an AUC of 0.81 with SN/SP 0.83/0.82 to distin-
guish PC (n= 88) from CP (n= 11) (Supplementary Table ST6a & b).
Improved diagnostic potential to differentiate EPC from BC or CP in
low CA19.9 as compared to high CA19.9 groups by combination of
TFFs is also evident from the analysis (Supplementary Table ST6a & b).
3.6. Diagnostic performance of TFF1-3 in the validation cohort
Next, we performed an independent blinded study for TFFs and
CA19.9 to validate their discriminatory potential in an independent
serum sample cohort consisting of BC (n= 8), CP (n = 27) and PC (n
=23).We also want to note that, our PC group in validation cohort ma-
jorly consisted of EPC (n= 18). In accordance with our earlier results,
we observed the diagnostic performance of combination of all TFFs
with an AUC value of 0.76, 0.84, 0.76, 0.82 in PC vs BC, PC vs CP, EPC
vs BC and EPC vs CP (Supplementary Fig. S6). While in validation set
CA19.9 demonstrated AUC value of 0.85, 0.71, 0.82, 0.66, interestingly
combination of TFFs and CA19.9 showed an AUC value of 0.85, 0.85,
0.85, 0.82 to differentiate PC vs BC, PC vs CP, EPC vs BC and EPC vs CP,
respectively, suggesting that in our validation set also, combination
panel of TFFs has improved the diagnosing ability of CA19.9 in detecting
EPC fromBC or CPwhich corroborateswith our earlier result from train-
ing set (Supplementary Fig. S6). Sensitivity and specificity value of indi-
vidual and combination of TFFs along with CA19.9 using same cutpoint
and models from the training set is shown in Supplementary Table ST7.
4. Discussion
Trefoil Factors have recently emerged as a prominent player in PC
pathogenesis. They have been identified by multiple individual studies
as top differentially expressed genes in the classical subtype of PC
[14,15]. From the biomarker point of view, TFF1, along with Lymphatic
vessel endothelial hyaluronan receptor 1 (LYVE1) and Regenerating
Family Member 1 Alpha (REG1A), has shown promising results as uri-
nary markers for PC [16]. Moreover, findings have suggested that TFF1
originates from PC, since its level sharply decreases after surgical re-
moval of the tumor [16]. The potential of TFFs to determine disease sta-
tus is also well evident in other cancers. For instance, TFF3 has been
demonstrated as a promising biomarker in colorectal cancer and gastric
cancers compared to conventional markers [17–19]. Though TFFs have
been proposed as potential diagnostic markers for PC in many studies,
to our knowledge, there has been no comprehensive study of all trefoil
family members for diagnosing this disease. Here, we analyzed the ex-
pression of TFFs along PC progression and evaluated their potential to
improve diagnosis of PC at early stage with better accuracy.
Preclinical exploration of differentially expressed genes frommicro-
array and GEO datasets, in conjunction with previously published re-
ports, suggest that TFFs are differentially upregulated in PC. Our
findings from cBioportal also showed very high expression of TFF1, 2,
and 3 in PC compared to 30 other malignancies listed in the databases.
Genes and proteins overexpressed in PanIN lesions hold the potential
to detect PC at early stages. While investigating early genetic aberra-
tions during PC pathogenesis, Guo et al. identified TFF1 overexpression
in the PanIN lesions [20]. Earlier, the transcriptomic analysis also re-
vealed that TFF1 was one of the top upregulated molecules in sporadic
and familial PanINs [21]. This lends credence to the use of TFF1 as a bio-
marker to identify cystic precursor lesions as well as early stages of PC.
Moreover, elevated expression of all TFF1, 2, and 3 were reported in
intraductal papillary-mucinous neoplasms (IPMNs) of the pancreas
[22]. Using IHC analysis, a significant proportion of pancreatic adenocar-
cinoma cells 23/45 (55%) and ampullary tumor cells, 8/10 (80%) were
shown to overexpress TFF1 [23]. In corroboration with earlier reports,
Table 1
Biomarker performance of individual TFF in PC training cohort.
Gene
name
Comparison
groups
Optimal
cutpoint
(pg/ml)
SN (at
optimal
cutpoint)
SP (at
optimal
cutpoint)
p
value
Total
cases
Total
controls
AUC PPV NPV Accuracy
TFF1 PC vs. BC N231.71 0.72 0.46 0.0078 152 104 0.61 0.66 0.52 0.61
PC vs. CP N162.07 0.84 0.36 0.0035 152 47 0.62 0.81 0.42 0.73
EPC vs BC N470.88 0.47 0.73 0.0078 78 104 0.64 0.57 0.65 0.62
EPC vs CP N692.43 0.38 0.87 0.0081 78 47 0.65 0.83 0.46 0.57
LPC vs BC N184.62 0.77 0.38 0.1751 69 104 0.56 0.45 0.71 0.53
LPC vs CP N141.44 0.86 0.32 0.0614 69 47 0.57 0.65 0.60 0.64
TFF2 PC vs. BC N5530.87 0.52 0.77 0.0012 114 92 0.64 0.74 0.56 0.63
PC vs. CP N3746.96 0.68 0.53 0.1840 114 40 0.58 0.80 0.36 0.64
EPC vs BC N5530.87 0.57 0.77 0.0013 58 92 0.66 0.61 0.74 0.69
EPC vs CP N3784.62 0.71 0.53 0.0931 58 40 0.61 0.68 0.55 0.63
LPC vs BC N5530.87 0.57 0.77 0.0617 52 92 0.59 0.52 0.71 0.65
LPC vs CP N3746.96 0.62 0.53 0.7040 52 40 0.53 0.63 0.51 0.58
TFF3 PC vs. BC N10,761.17 0.53 0.64 0.0642 146 98 0.58 0.69 0.48 0.57
PC vs. CP b9818.27 0.46 0.65 0.1692 146 46 0.55 0.81 0.27 0.50
EPC vs BC N10,920.53 0.56 0.64 0.0931 77 98 0.61 0.55 0.64 0.60
EPC vs CP b11,255.36 0.52 0.57 0.5177 77 46 0.52 0.66 0.41 0.53
LPC vs BC N12,878.31 0.38 0.74 0.7995 64 98 0.52 0.49 0.65 0.60
LPC vs CP b9590.23 0.55 0.65 0.0325 64 46 0.61 0.68 0.50 0.58
Table 2
Biomarker performance of combination of TFFs and CA19.9 in training cohort.
Assay group Prediction models Optimal
cutpoint
90% SP AUC
SN SP SN
PC vs BC CA19.9 0.86 0.81 0.76 0.91
TFF1 + TFF2 + TFF3 0.73 0.54 0.33 0.66
TFF1 + TFF2 + TFF3 + CA19.9 0.85 0.92 0.85 0.94
PC vs CP CA19.9 0.88 0.81 0.74 0.91
TFF1 + TFF2 + TFF3 0.47 0.92 0.47 0.76
TFF1 + TFF2 + TFF3 + CA19.9 0.90 0.92 0.90 0.94
EPC vs BC CA19.9 0.84 0.81 0.69 0.90
TFF1 + TFF2 + TFF3 0.76 0.54 0.38 0.69
TFF1 + TFF2 + TFF3 + CA19.9 0.75 0.96 0.79 0.93
EPC vs CP CA19.9 0.87 0.81 0.67 0.89
TFF1 + TFF2 + TFF3 0.51 0.90 0.44 0.76
TFF1 + TFF2 + TFF3 + CA19.9 0.92 0.92 0.92 0.93
LPC vs BC CA19.9 0.82 0.95 0.82 0.93
TFF1 + TFF2 + TFF3 0.77 0.43 0.20 0.59
TFF1 + TFF2 + TFF3 + CA19.9 0.86 0.97 0.86 0.95
LPC vs CP CA19.9 0.81 0.96 0.82 0.93
TFF1 + TFF2 + TFF3 0.77 0.64 0.39 0.77
TFF1 + TFF2 + TFF3 + CA19.9 0.88 0.95 0.88 0.96
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our study also revealed higher expression of TFFs in well-differentiated
PC tumors compared to undifferentiated tumors [24]. In addition, in our
study strong expression of TFFs in metastatic liver tissues was in agree-
ment with an earlier study byMoffit et al. [15]. While our present work
and other previous studies observed overexpression of TFF3 in the Islets
of Langerhans, the pathophysiological relevance of this overexpression
is still unknown. Serum TFF3 is known to have a proliferative effect on
pancreatic islet β-cells and therefore can therapeutically benefit type 1
and 2 diabetic patients [25]. Also, overexpression of TFF3 in the liver
of diabetic and obese mice was shown to improve glucose tolerance
by decreasing blood glucose levels and inhibiting genes involved in glu-
coneogenesis [26]. While insulin resistance and glucose intolerance are
associated with PC pathogenesis, it becomes imperative to investigate
the role of TFF3 in diabetes, a well-known risk factor for PC [27]. Of
note, we observed age-dependent increase in TFFs level in PC serum
samples. As PC is an age-dependent disease, the elevated levels in TFFs
level might be due to increasing numbers of PanIN in pancreas [28]. In
this reference, it is also reported earlier that high-grade PanIN lesions
were more likely to be found in older patients and in those with diabe-
tes mellitus [29]. As TFFs are highly expressed in PanIN, so the age-
dependent increase in PanIN as well as PC progression might be a plau-
sible cause for higher TFFs expression in N64 age. However, in the light
of the lack of tissue samples across various age group, it is very difficult
to say the real reason for elevated TFFs with age. Looking at this trend,
we analyzed TFFs diagnostic performance after age adjustment. Inter-
estingly, combination of all TFFs has shown better performance in dif-
ferentiating PC or EPC from CP (AUC of 0.76 without age adjustment
and 0.85 with age adjustment) (Table 2, Supplementary Table ST4b).
Additionally, when we adjusted age for both low CA19.9 and high
CA19.9 group, we have observed that combination of TFFs demon-
strated AUC value of 0.92 with age adjustment as compared to AUC
value of 0.82 without age adjustment to distinguish PC from CP in low
CA19.9 group, whereas in high CA19.9 group AUC value was 0.81 with
age adjustment as compared to 0.73without age adjustment to identify
PC from CP (Supplementary Tables ST5a-b and ST6a-b).
Although CA19.9 is by far the most commonly used and standard
biomarker for PC, several drawbacks of CA19.9 persist and limit its
use. These include false negative results in the 5–10% of patients with
a Lewis negative genotype, elevated level in other cancers, and GI dis-
eases [12,30,31]. Multi-marker diagnostic panels have previously
shown promise for many cancers such as breast and CRC [32–35]. Our
group and others investigated the potential of combining CA19.9 with
other biomarkers including intercellular adhesion molecule 1 (ICAM-
1), osteoprotegerin (OPG), osteopontin (OPN), human epididymis se-
cretory protein 4 (HE4), and neutrophil gelatinase-associated lipocalin
(NGAL) to improve diagnostic performance [36–39]. While all these
studies demonstrated the ability to differentiate PC cases from a healthy
control, they did not prove to be beneficial for prediagnostic risk assess-
ment for PC [37]. Therefore, ongoing efforts to validate the circulating
levels of additional biomarkers which are differentially expressed in
pancreatic tumors and preneoplastic lesions will be beneficial to in-
crease the detection of PC at early stage. Thus, TFFs hold a promise as
a potential biomarker because of their elevated expression in PanIN
and PC. While our results revealed the failure of individual TFFs to dis-
criminate PC from BC, the combination of TFFs with CA19.9 demon-
strated a surprisingly better diagnostic performance than CA19.9
alone. In addition, this combination of TFFs with CA19.9 improved the
diagnostic potential of distinguishing EPC, a stage which determines
the possibility of surgical resection, from BC and CP as compared to
CA19.9 alone in both training and validation cohort. Another unique
finding of our study demonstrated that the combination of TFF1–3 can
differentiate between PC and control groups in patients with low
Fig. 4. Evaluation of the diagnostic significance of TFFs in combination with CA19.9 (a) To evaluate diagnostic significance of the TFFs in combination with CA19.9 for the training set, ROC
curves and AUC analyses was carried out for TFF1, TFF2, TFF3 and is presented to distinguish different control groups from PC. The value of the area under curve (AUC) is represented in
each box. BC, benign control group; CP, chronic pancreatitis; EPC, early-stage pancreatic cancer (stage 1 and 2); PC, pancreatic cancer. The ROC curve shows comparable performance
among all individual TFFs to distinguish different control groups from PC. ROC curves and AUC values for the combination of TFF1-3 and CA19.9 to distinguish different control groups
from PC. (b). Evaluation of the diagnostic performance of TFF1-3 in CA19.9 low (b37 U/ml) and high (N37 U/ml) groups. ROC curves and AUC values for the combination of TFF1–3 in
low CA19.9 (b37 U/ml) and high CA19.9 (N37 U/ml) groups, to distinguish different control groups from PC. The value of the area under curve (AUC) is represented in each box. The
ROC curve showed that combination of TFF1–3 retains their diagnostic potential in the setting of low CA19.9, to differentiate between PC and control groups. The AUC is represented in
each box. BC, benign control group; CP, chronic pancreatitis; EPC, early-stage pancreatic cancer (stage 1 and 2); PC, pancreatic cancer. The ROC curve showed that combination of TFFs
and CA19.9 has better diagnostic accuracy over CA19.9 to distinguish different control groups from PC as well as EPC.
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CA19.9 expression (b37 U/ml). Taken together, our study suggests the
use of TFF1–3 and CA19.9 combination as a potential diagnostic marker
for PC diagnosis.
The strength of our study is the comprehensive evaluation of TFFs
alone or in combination with CA19.9 as potential PC biomarkers by
employing human tissues, large cohort of serum samples, and the use
of a mouse progression model of PC. While our study strongly suggests
that a combination of TFF1–3 and CA19.9 discriminates early stage PCs
from BCs with improved sensitivity and specificity, we also observed
decreased TFFs expression in late stages of PC. Though the underlying
mechanisms for this downregulation are still unknown, alteration in
methylation patterns between the well and poorly differentiated PCs
might be one of the reasons [40]. Earlier studies have shown
hypomethylated TFF2 promoter in 84% of PC tissues and treatment
with DNAmethyltransferase inhibitor and histone deacetylase inhibitor
in PC cell line, where TFF2 is silenced by methylation, led to the activa-
tion of this gene [41]. Recent studies using spontaneous mouse model
demonstrated that loss of TFF1 and TFF2 enhanced PanIN progression
along with PC, which reveals their tumor-suppressing role [42,43].
Nevertheless, TFF1 and TFF2 have been shown to increase PC cell
proliferation and migration [24,44]. Moreover, higher TFF1 expression
was found in central tumors while decreased expression was observed
in the invasion front of human PDAC however, retained TFF1 expression
in the invasion front was associated with positive lymphatic invasion,
lymph node metastasis and poor survival of PC patients [45]. However,
based on our findings and earlier reports, we believe that TFFs are very
critical factors in PC pathogenesis and that they warrant precise study
with mouse models and in vivo lineage tracing studies.
The limitations of our study include the small sample size of BC in
the validation cohort. Although, analysis in our validation cohort has
demonstrated that combination of TFFs and CA19.9 (AUC = 0.82) im-
proves the overall efficacy of CA19.9 (AUC = 0.66) to differentiate EPC
from CP (Supplementary Fig. S6, Supplementary Table ST7), however,
addition of TFFs could neither add nor reduce the diagnostic power of
CA19.9 to differentiate PC from BC which differed from our analysis in
training set. This finding further necessitates an extensive blinded vali-
dation study with a large number of BC samples in the future. In addi-
tion, CA19.9 and TFFs are shown to be elevated in other cancers, but
our study has investigated the diagnostic potential of this biomarker
panel in PC only, and therefore further research in other cancers as
also warranted [5,31]. Furthermore, multi-institutional validation and
cross-validation for this panel are needed to make it a reliable
multimarker panel. Moreover, TFF1 has shown to be a promising urine
biomarker for PC [16]. Based on previous studies and our analysis
from the training and validation sets also suggest that TFF1 should be
given more emphasis for future biomarker and functional studies, as it
performed better in both datasets to differentiate between EPC and
CP.Moreover, itwill be interesting to investigate their diagnostic perfor-
mance in pancreatic juice and urine as well. Alongside the prognostic
significance, ability of TFFs to predict recurrence and drug-response in
PC patients, are interesting aspects to investigate in the future as
CA19.9 has been observed to predict post-operative recurrence as well
as response to chemotherapy in PC patients [13]. Another limitation in
our study was a very small sample number in age-adjusted low
CA19.9 (b37 U/ml) group, though our interesting finding has suggested
that combination of TFFs has the ability to differentiate EPC from CP in
age-adjusted low CA19.9 group with an AUC value of 0.94 (Supplemen-
tary Table ST6a). However, considering the limitation of small sample
number and their diagnostic potential in those groups warrants investi-
gating the potential of combination of TFFs in low and high CA19.9
groupwith age adjustment in a larger cohort of patient sample in future.
Moreover, we have analyzed individual TFFs expression in patient sam-
ple BC N 1.2mg/dL and BC b 1.2mg/dL samples to identify whether TFFs
can differentiate between non carcinoma and carcinoma related jaun-
dice. We didn't observe any significant difference of TFF1 and TFF3 ex-
pression with high and low bilirubin levels. At the same time, we
observed differences in CA19.9 and TFF2 (P b .05, Mann –Whitney U
Test) across these groups suggesting TFF1 or TFF3 could be potential
markers that are not be affected by acute biliary obstructions or non-
carcinoma related jaundice. Thus, evaluating TFF 1 and 3 in conjunction
with CA19.9 can improve the performance of the differentiation of non-
cancer related jaundice or acute biliary obstruction from early stage PC
(Data not shown). Thus, evaluating TFFs clinical utility in differentiating
cancer-related jaundice and non-cancer related jaundiced with a large
cohort of clinical samples would be next logical step as CA19.9 gets ele-
vated even in non-carcinoma conditions like obstructive jaundice and
produce false positive result [46].
To translate this diagnostic panel from bench to bedside, more ef-
fort should be made to uncover the molecular landscape of TFFs in
PC. Specifically, it would be interesting to explore whether increased
levels of TFFs, both in serum and tissue, are the drivers or the conse-
quence of disease progression. TFF1 was previously correlated with
increased PC cell proliferation and metastasis [44], and recombinant
treatment with TFF2 has induced PC cell migration [24]. By contrast,
loss of TFF2 from a newly defined progenitor compartment in PC,
coined the pancreatic duct gland, has shown to accelerate IPMN for-
mation [42].
Recently, Collisson et al. identified three PC subtypes: classical,
quasi-mesenchymal, and exocrine-like, based on gene signatures
from human and mouse PC samples. They observed that classical
subtype is more gemcitabine-resistant compared to other subtypes
[14]. In another study, the Moffitt group identified two subgroups,
‘classical’ and ‘basal-like’, where basal-like tumors showed a strong
trend toward a better response to adjuvant therapy. Surprisingly,
both groups have discovered family members of TFFs to be critical
contributors in the classical subtype of PC. Identification of PC
subtyping has created a new avenue for PC precision medicine. This
will pave the way to improved clinical outcomes and therapeutic re-
sponse based on intrinsic molecular variabilities among patient
groups that clinically progress at different rates and may respond dif-
ferently to administered therapies [14,15]. We believe that
untangling the complex mechanism of PC progression, as well as un-
derstanding the genomic landscape of PC subtypes, is thus urgently
required for the development of novel screening strategies and che-
mopreventive approaches for PC. Uncovering the role of subtype-
specific molecules like TFFs is much needed.
The identification of an early diagnostic marker is gaining unprece-
dented attention not only because it provides insight into disease occur-
rence but also provides the impetus for developing novel strategies for
therapeutic intervention. Importantly, both our training and validation
sets analysis suggested that combination of TFFs and CA19.9 are able
to differentiate EPC from chronic pancreatitis, a perplexing state
which lead to difficulties in identifying PC at early stages. Our combina-
tion of TFFs has demonstrated anAUC value of 0.76 (without age adjust-
ment) and 0.85 (with age adjustment) to differentiate EPC, a surgically
resectable stage fromCP (Fig. 2 and Supplementary Fig. S4a). Our results
indicated that the combination of CA19.9 and TFFs can differentiate
early stages of pancreatic cancer, which is the stage for surgically resect-
able pancreatic cancer, from benign controls and chronic pancreatitis.
Thus, we anticipate that combination of TFF1, 2, 3 may not be a useful
marker for identifying tumor resectability with high sensitivity and
specificity but combination of TFFs andCA19.9will have the clinical util-
ity for early detection of surgically resectable PC. While still in its in-
fancy, validation of TFFs in combination with CA19.9 in serum will not
only predict the presence of PC at early stage but may also have utility
in stratifying patients for appropriate therapeutic regimen selection,
given that TFFs have been shown to be highly upregulated in classical
subtype of PC. Apart from protein biomarkers, very recently, circulating
tumor DNA (ctDNA), circular RNA, miRNAs, lncRNA, exosomes have
gained immense attention asminimally invasive tool for early detection
and diagnosis of cancer, however efforts are still going on to improve
their isolation techniques, stability, reliability, sensitivity, cost of
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analysis, storage measures for bringing them into clinics [47–50]. Fur-
thermore, recent evidence of conventional biomarker coupled with
KRAS mutations in ctDNA has provided optimism as a diagnostic and
prognostic marker for PC. However, protein-based biomarkers still
stand out as better diagnostics than other emerging biomarkers, pri-
marily because of their superior stability, enhanced availability in the
serumandwell-established protocols. More studies are highly desirable
to combine the benefit of both protein-based biomarkers alongwith ge-
nomic marker for diagnosis of lethal PC [51].
Based on our knowledge from the published literature, this study is
the first of its kind to demonstrate the potential role of TFF1, TFF2, and
TFF3 as serum-based markers for diagnosing early-stage PC. However,
the establishment of a clinically valuable biomarker panel requires ex-
haustive validation and cross-sectional multicenter studies, and this is
our ongoing research focus for this panel. Our results suggest compel-
ling evidence from publicly available datasets, tissue, and serum analy-
sis that TFF1, TFF2, and TFF3, along with CA19.9, can be a useful
biomarker for identifying PC.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ebiom.2019.03.056.
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